Uptravi (generic name: selexipag) is prescribed for the treatment of pulmonary arterial hypertension (PAH, WHO Group I), a condition characterized by high pulmonary artery pressure that strains the heart and lungs.
Selexipag is a prostacyclin receptor agonist that will selectively stimulate the prostacyclin IP receptor on vascular smooth muscle cells, promoting vasodilation, inhibiting vascular remodeling, and reducing platelet aggregation. This helps to slow disease progression and reduce the risk of hospitalization,
Dosage
Follow the instructions on the label of the Uptravi box. If you have any questions, consult with a doctor or pharmacist.
The typical oral dosing regimen begins at 200 mcg twice daily, with food, approximately 12 hours apart. Typically, the dose is gradually increased weekly in 200 mcg increments until the highest tolerated dose is reached, up to a maximum of 1600 mcg twice daily.
If a patient misses a dose and the next scheduled dose is more than 6 hours away, take it as soon as remembered. If less than 6 hours remain, skip the missed dose and continue with your normal schedule. Don’t stop taking the medicine without consulting a doctor. In the event of an accidental overdose, call 911 or go to an emergency medical care center immediately.
Storage
Tablets should be stored at 20–25 °C (68–77 °F) in original packaging, protected from moisture and out of children’s reach. If in any doubt, consult our blog on safe medicine management.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.Â
Read the information leaflet that comes with the medication.
If a sudden allergic reaction (anaphylaxis) occurs shortly after taking Uptravi, with symptoms like swelling of the face, tongue, or throat making it difficult to breathe or swallow, or there is wheezing, hives, rash, blistering, or peeling of the skin, call a doctor or 911 right away, or go to an emergency room immediately.
Most people who use Uptravi do not experience any adverse side effects. Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include:
- headache
- diarrhea
- jaw pain
- nausea and vomiting
- myalgia
- pain in arms or legs
- flushing
- joint pain
- anemia
- rash
- decreased appetite
- upper respiratory symptoms.
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Uptravi is approved for adult patients with pulmonary arterial hypertension (PAH, WHO Group I), a chronic condition marked by constriction and remodeling of pulmonary arteries, leading to elevated blood pressure within these vessels.
PAH symptoms include shortness of breath, fatigue, dizziness, chest pain, swelling of ankles or legs, and reduced ability to perform exercise due to impaired blood flow to the lungs and heart.